Literature DB >> 14572778

Pentoxifylline reduces acute lung injury in chronic endotoxemia.

Christopher Michetti1, Raul Coimbra, David B Hoyt, William Loomis, Wolfgang Junger, Paul Wolf.   

Abstract

BACKGROUND: Pentoxifylline (PTX) attenuates end-organ injury in models of sepsis and hemorrhage. PTX is thought to act by inhibiting phosphodiesterase, thus increasing cAMP and decreasing tumor necrosis factor-alpha (TNF-alpha) synthesis. The effects of PTX on neutrophil and endothelial cell adhesion molecules and, ultimately, organ injury in a chronic endotoxemia model have not been studied. We hypothesized that continuous infusion of PTX reduces acute lung injury (ALI) caused by chronic lipopolysaccharide (LPS) exposure.
MATERIALS AND METHODS: Male Sprague-Dawley rats were given continuous infusion of LPS, PTX + LPS combined, or saline (sham) by implantable pumps. Neutrophil CD11b expression, lung histopathology, lung intercellular adhesion molecule-1 (ICAM-1) expression assessed by immune staining, serum TNF-alpha, serum interleukin-6 (IL-6), and bronchoalveolar lavage (BAL) IL-8 were evaluated at different time points. Lung injury was graded in a blinded fashion from 0 (normal) to 4 (severe) for interstitial inflammation, neutrophil infiltration, congestion, and edema. Total lung injury score (TLIS) was calculated by adding listed categories. White cell count in the peripheral blood and in the BAL was also performed.
RESULTS: Animals treated with PTX + LPS showed a significant reduction in lung injury score, a marked decrease in ICAM-1 expression, and a significant decrease in IL-8 levels in the BAL and serum IL-6 levels when compared with LPS-treated animals.
CONCLUSIONS: Continuous infusion of PTX reduces ALI caused by chronic endotoxemia. The effect seems to be a result of decreased expression of endothelial and epithelial ICAM-1 and modulation of proinflammatory cytokine synthesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572778     DOI: 10.1016/s0022-4804(03)00219-1

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury.

Authors:  L J Mark Cross; Michael A Matthay
Journal:  Crit Care Clin       Date:  2011-04       Impact factor: 3.598

2.  Therapeutic effect of intravenous infusion of perfluorocarbon emulsion on LPS-induced acute lung injury in rats.

Authors:  Shike Hou; Hui Ding; Qi Lv; Xiaofeng Yin; Jianqi Song; Ning Xu Landén; Haojun Fan
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

3.  Hypertonic saline and pentoxifylline enhance survival, reducing apoptosis and oxidative stress in a rat model of strangulated closed loop small bowel obstruction.

Authors:  Gustavo Scapini; Roberto Rasslan; Natalie Chaves Cayuela; Miguel Angelo Goes; Marcia Kiyomi Koike; Edivaldo Massazo Utiyama; Edna Frasson de Souza Montero; Samir Rasslan
Journal:  Clinics (Sao Paulo)       Date:  2019-06-06       Impact factor: 2.365

4.  Influence of Anemia on Postoperative Cognitive Function in Patients Undergo Hysteromyoma Surgery.

Authors:  Zhijian You; Lesi Chen; Hongxia Xu; Yidan Huang; Jinglei Wu; Jiaxuan Wu
Journal:  Front Mol Biosci       Date:  2021-11-26

Review 5.  A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19.

Authors:  Gomaa Mostafa-Hedeab; Hayder M Al-Kuraishy; Ali I Al-Gareeb; Philippe Jeandet; Hebatallah M Saad; Gaber El-Saber Batiha
Journal:  Inflammopharmacology       Date:  2022-04-29       Impact factor: 5.093

Review 6.  Drug therapy for the prevention and treatment of bronchopulmonary dysplasia.

Authors:  Anjali Iyengar; Jonathan M Davis
Journal:  Front Pharmacol       Date:  2015-02-16       Impact factor: 5.810

Review 7.  Pulmonary Protection Strategies in Cardiac Surgery: Are We Making Any Progress?

Authors:  Emad Al Jaaly; Mustafa Zakkar; Francesca Fiorentino; Gianni D Angelini
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

Review 8.  Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?

Authors:  Farnoosh Seirafianpour; Samaneh Mozafarpoor; Nima Fattahi; Afsaneh Sadeghzadeh-Bazargan; Melika Hanifiha; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2020-06-26       Impact factor: 3.858

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.